Pyrotinib dimaleate
≥98%
- Product Code: 102199
CAS:
1397922-61-0
| Molecular Weight: | 815.22 g./mol | Molecular Formula: | C₄₀H₃₉ClN₆O₁₁ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Pyrotinib dimaleate is primarily used in the treatment of HER2-positive breast cancer. It functions as a tyrosine kinase inhibitor, specifically targeting and blocking the HER2 receptor, which is often overexpressed in certain types of breast cancer. By inhibiting this receptor, it helps to slow down or stop the growth of cancer cells. This medication is particularly beneficial for patients who have not responded well to other HER2-targeted therapies. It is commonly administered orally, making it a convenient option for ongoing treatment. Clinical studies have shown that pyrotinib dimaleate can significantly improve progression-free survival in patients with advanced or metastatic HER2-positive breast cancer, especially when used in combination with other chemotherapeutic agents. Its role in managing this aggressive form of cancer highlights its importance in modern oncology.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Yellow Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $1,022.08 |
+
-
|
| 0.005 | 10-20 days | $2,611.64 |
+
-
|
Pyrotinib dimaleate
Pyrotinib dimaleate is primarily used in the treatment of HER2-positive breast cancer. It functions as a tyrosine kinase inhibitor, specifically targeting and blocking the HER2 receptor, which is often overexpressed in certain types of breast cancer. By inhibiting this receptor, it helps to slow down or stop the growth of cancer cells. This medication is particularly beneficial for patients who have not responded well to other HER2-targeted therapies. It is commonly administered orally, making it a convenient option for ongoing treatment. Clinical studies have shown that pyrotinib dimaleate can significantly improve progression-free survival in patients with advanced or metastatic HER2-positive breast cancer, especially when used in combination with other chemotherapeutic agents. Its role in managing this aggressive form of cancer highlights its importance in modern oncology.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :